BILKULONLINE
Mumbai, Aug 4: Alembic Pharmaceuticals Limited reported its consolidated financial results for the first quarter ended 30th June, 2023.
Financial Highlights
- Net Sales grew 18% to Rs.1486 crores for the quarter.
- Net Profit for the quarter at Rs.121 crores.
Pranav Amin, Managing Director, Alembic Pharmaceuticals Limited said “The company grew in all the business segments with India outperforming the market with 9% growth, Ex US generics grew 46%, API grew 31% and the US generics business grew 6%. We have also started commercializing products from our Oncology and Injectable Facilities”
Operational Highlights
India Branded Business
- Branded Business up by 9% to Rs. 524 Cr in the quarter.
- Branded Business reflected growth of 11%* better than industry growth of 9%*.
- Specialty therapies recorded growth of 12%* vis a vis industry growth of 7%*.
- Acute therapies recorded growth of 16%* vis a vis Industry growth of 10%*. In Anti Infective, Industry has shown growth of 10%* where as Alembic recorded 19%* growth.
- Animal Health business recorded growth of 11% over PY Q1.
* IQVIA Qtr June ’23
International Business
- US Generics up 6% to Rs. 390 crores in the quarter.
- Ex-US International Formulations grew 46% to Rs. 266 Crores in the quarter.
- 5 ANDA approvals received during the quarter; 184 Cumulative ANDA approvals.
- 5 ANDA filings during the quarter; Cumulative ANDA filings at 250.
API Business
- API business grew 31% at Rs. 305 crores in the quarter.
- 131 cumulative DMF Filings.
The summary of Total Revenue is as under:
(Rs in Crores)
| Particulars | Q1 FY24 | Q1 FY23 | % Change |
| Formulation | |||
| USA
Ex- US |
390
266 |
367
182 |
6%
46% |
| India | 524 | 480 | 9% |
| API | 305 | 233 | 31% |
| Total | 1486 | 1262 | 18% |